Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flecainide: long-term treatment using a reduced dosing schedule.

D Flowers, D O'Gallagher, V Torres

    The American Journal of Cardiology
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    High-Statistics Measurement of Collins and Sivers Asymmetries for Transversely Polarized Deuterons.

    Physical review letters·2024
    Same author

    Final COMPASS Results on the Transverse-Spin-Dependent Azimuthal Asymmetries in the Pion-Induced Drell-Yan Process.

    Physical review letters·2024
    Same author

    Laparoscopic Liver Resection: A South American Experience with 2887 Cases.

    World journal of surgery·2020
    Same author

    Resveratrol-cyclodextrin complex affects the expression of genes associated with lipid metabolism in bovine in vitro produced embryos.

    Reproduction in domestic animals = Zuchthygiene·2018
    Same author

    Validation of 3D skin imaging for objective repeatable quantification of severity of atrophic acne scarring.

    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)·2018
    Same author

    Development of an atrophic acne scar risk assessment tool.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2017
    Same journal

    Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

    The American journal of cardiology·2026
    Same journal

    ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

    The American journal of cardiology·2026
    Same journal

    Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

    The American journal of cardiology·2026
    Same journal

    Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

    The American journal of cardiology·2026
    Same journal

    Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

    The American journal of cardiology·2026
    Same journal

    Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

    The American journal of cardiology·2026
    See all related articles

    Flecainide at a reduced dose effectively prevents ventricular tachycardia (VT) in many patients. This antiarrhythmic drug prolongs refractory periods, improving chronic VT prevention and patient outcomes.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Flecainide, an antiarrhythmic drug, was initially prescribed at 200 mg twice daily.
    • Early toxicity led to a dosage reduction to 100 mg twice daily for ventricular tachycardia (VT) management.

    Purpose of the Study:

    • To evaluate the chronic efficacy of flecainide at a reduced dose (100 mg twice daily) in preventing VT.
    • To assess the electrophysiological effects of flecainide on refractory periods.

    Main Methods:

    • Programmed electrical stimulation was performed in 40 patients with VT.
    • Flecainide's efficacy in preventing VT induction and its effects on the effective refractory period were analyzed.
    • Patients were followed for a mean of 11 months after discharge on flecainide therapy.

    Main Results:

    Related Experiment Videos

    • Flecainide prevented VT induction in 65% of patients at the reduced dose.
    • The drug significantly prolonged the effective refractory period in patients protected from VT.
    • Long-term follow-up showed favorable outcomes, with most patients remaining stable on flecainide therapy.

    Conclusions:

    • Flecainide, at 100 mg twice daily, is effective in preventing chronic VT in a majority of patients.
    • The antiarrhythmic effect is associated with a significant increase in effective refractory periods.
    • The reduced dosage of flecainide demonstrates a favorable safety and efficacy profile for long-term VT management.